The third quarter earnings season is ongoing with key companies like Coal India, Tata Steel, and Indian Oil set to announce ...

The second indigenous CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" ...

Syngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects ...

Here's a list of buy/sell recommendations for today from three analysts: Ankush Bajaj, Raja Venkatraman, and MarketSmith ...

Therapy will cost Rs 35 to 50 lakh. India sees around 1.20 lakh new blood cancer cases and over 70,000 deaths annually from ...